uniQure N.V (UQ1) - Net Assets
Based on the latest financial reports, uniQure N.V (UQ1) has net assets worth €228.75 Million EUR (≈ $267.43 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€888.38 Million ≈ $1.04 Billion USD) and total liabilities (€659.64 Million ≈ $771.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of uniQure N.V to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €228.75 Million |
| % of Total Assets | 25.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | -102.77% |
| 10-Year Change | N/A |
| Growth Volatility | 79.54 |
uniQure N.V - Net Assets Trend (2016–2024)
This chart illustrates how uniQure N.V's net assets have evolved over time, based on quarterly financial data. Also explore UQ1 asset base for the complete picture of this company's asset base.
Annual Net Assets for uniQure N.V (2016–2024)
The table below shows the annual net assets of uniQure N.V from 2016 to 2024. For live valuation and market cap data, see uniQure N.V stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-6.75 Million ≈ $-7.89 Million |
-103.25% |
| 2023-12-31 | €207.67 Million ≈ $242.79 Million |
-56.37% |
| 2022-12-31 | €476.01 Million ≈ $556.50 Million |
-20.10% |
| 2021-12-31 | €595.78 Million ≈ $696.52 Million |
+144.27% |
| 2020-12-31 | €243.91 Million ≈ $285.15 Million |
-24.50% |
| 2019-12-31 | €323.06 Million ≈ $377.69 Million |
+79.87% |
| 2018-12-31 | €179.61 Million ≈ $209.98 Million |
+100.99% |
| 2017-12-31 | €89.36 Million ≈ $104.47 Million |
+40.43% |
| 2016-12-31 | €63.63 Million ≈ $74.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to uniQure N.V's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 73390700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.12 Billion | % |
| Total Equity | €-6.75 Million | 100.00% |
uniQure N.V Competitors by Market Cap
The table below lists competitors of uniQure N.V ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CVR Partners LP
NYSE:UAN
|
$1.26 Billion |
|
LIBERTY LAT.AMER.C DL-01
F:1LLC
|
$1.26 Billion |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
$1.26 Billion |
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
$1.26 Billion |
|
SkiStar AB (publ)
ST:SKIS-B
|
$1.26 Billion |
|
HUANLEJIA Food Group Co. Ltd.
SHE:300997
|
$1.26 Billion |
|
RPC Inc
NYSE:RES
|
$1.26 Billion |
|
Hengdian Group Tospo Lighting Co Ltd
SHG:603303
|
$1.26 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in uniQure N.V's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 207,670,000 to -6,752,000, a change of -214,422,000 (-103.3%).
- Net loss of 239,556,000 reduced equity.
- New share issuances of 2,123,000 increased equity.
- Other factors increased equity by 23,011,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-239.56 Million | -3547.93% |
| Share Issuances | €2.12 Million | +31.44% |
| Other Changes | €23.01 Million | +340.8% |
| Total Change | €- | -103.25% |
Book Value vs Market Value Analysis
This analysis compares uniQure N.V's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.85 | €17.34 | x |
| 2018-12-31 | €4.81 | €17.34 | x |
| 2019-12-31 | €7.39 | €17.34 | x |
| 2020-12-31 | €5.45 | €17.34 | x |
| 2021-12-31 | €12.87 | €17.34 | x |
| 2022-12-31 | €10.13 | €17.34 | x |
| 2023-12-31 | €4.34 | €17.34 | x |
| 2024-12-31 | €-0.14 | €17.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently uniQure N.V utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -883.35%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-51.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -115.31% | -292.35% | 0.13x | 2.99x | €-79.74 Million |
| 2017 | -88.70% | -604.72% | 0.06x | 2.35x | €-88.20 Million |
| 2018 | -46.38% | -738.25% | 0.04x | 1.53x | €-101.26 Million |
| 2019 | -38.45% | -1705.82% | 0.02x | 1.39x | €-156.51 Million |
| 2020 | -51.26% | -333.27% | 0.11x | 1.40x | €-149.41 Million |
| 2021 | 55.32% | 62.90% | 0.65x | 1.36x | €270.01 Million |
| 2022 | -26.64% | -119.07% | 0.15x | 1.48x | €-174.39 Million |
| 2023 | -148.54% | -1947.09% | 0.02x | 4.00x | €-329.25 Million |
| 2024 | 0.00% | -883.35% | 0.05x | 0.00x | €-238.88 Million |
Industry Comparison
This section compares uniQure N.V's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,853,365,206
- Average return on equity (ROE) among peers: -33.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| uniQure N.V (UQ1) | €228.75 Million | -115.31% | 2.88x | $1.26 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $344.93 Million | -8.14% | 0.08x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.73 Billion | -7.29% | 0.04x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $2.19 Million | -197.55% | 0.15x | $3.31 Million |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more